| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2556 | 2016 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863, 2015 | 2182 | 2015 |
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ... New England Journal of Medicine 357 (21), 2123-2132, 2007 | 1977 | 2007 |
| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1681 | 2016 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1522 | 2015 |
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer … DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ... J Clin Oncol 29 (9), 1125-1132, 2011 | 1503 | 2011 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 999 | 2016 |
| Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy … RZ Orlowski, A Nagler, P Sonneveld, J Bladé, R Hajek, A Spencer, ... Journal of Clinical Oncology 25 (25), 3892-3901, 2007 | 782 | 2007 |
| Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma MA Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, EA Stadtmauer, ... Leukemia 23 (11), 2147-2152, 2009 | 536 | 2009 |
| Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ... Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011 | 466 | 2011 |
| International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ... Journal of clinical oncology 31 (18), 2347, 2013 | 445 | 2013 |
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation … A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, ... J Clin Oncol 27 (11), 1788-1793, 2009 | 437 | 2009 |
| Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse F van Rhee, F Lin, JO Cullis, A Spencer, NC Cross, A Chase, ... | 429 | 1994 |
| Thalidomide for treatment of multiple myeloma: 10 years later A Palumbo, T Facon, P Sonneveld, J Blade, M Offidani, F Gay, P Moreau, ... Blood, The Journal of the American Society of Hematology 111 (8), 3968-3977, 2008 | 405 | 2008 |
| Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a … F Gay, S Oliva, MT Petrucci, C Conticello, L Catalano, P Corradini, ... The lancet oncology 16 (16), 1617-1629, 2015 | 364 | 2015 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 336 | 2020 |
| Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data A Palumbo, S Bringhen, SK Kumar, G Lupparelli, S Usmani, A Waage, ... The lancet oncology 15 (3), 333-342, 2014 | 336 | 2014 |
| International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem … A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, ... Journal of clinical oncology 32 (6), 587, 2014 | 311 | 2014 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 297 | 2018 |
| BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1 SJ Hogg, SJ Vervoort, S Deswal, CJ Ott, J Li, LA Cluse, PA Beavis, ... Cell reports 18 (9), 2162-2174, 2017 | 277 | 2017 |
